Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIMBISCH: Intensified Insulin Therapy for Restenosis Prevention After Peripheral Angioplasty
NCT01150617Phase 4Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Dec 2008
- Primary completion
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) and Peripheral Arterial Disease (PAD) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Incidence of angiographic restenosis at 6 months. Started Dec 2008; status: terminated.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT01150617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01150617.